Business Description

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products - AMITIZA, its lead product, and RESCULA - and a late-stage pipeline of product candidates in clinical development for orphan disease areas.  VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1.  Sucampo has an option for the North American rights to CPP1-x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S.  A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.

Company Info

Address:
805 King Farm Boulevard
Suite 550
Rockville, MD 20850

Telephone:
301-961-3400

Fax:
301-961-3440

Email:
info@sucampo.com

Industry Classifications

Sector:
Healthcare

Industry:
Drug Manufacturers

NAICS:
Pharmaceutical Preparation Manufacturing (325412)

SIC:
Pharmaceutical Preparations (2834)